Almonty Industries Inc.
ALMNASDAQ
USReal-Time Price
USReal-Time Price$8.14USD
-0.64 (-7.24%)Today
$8.24+0.10 (+1.23%)After HoursLast quote · Nov 10, 2026, 6:32 PM ET
Investors Sentoments
Sign in to share your view.
BTI Score
BASIC required or higher
View pricingBTI Fair Market Cap
$744.07M
+210.41% vs fair
Materials & Mining
High Risk
Almonty Industries Inc. (ALM) Business Model
How does Almonty Industries Inc. (ALM) make money? A breakdown of revenue segments, margins, competitive moat and the unit economics behind the business.
Showing saved analysis from 06 / 10 / 2026; an updated analysis is currently unavailable.
How the company makes money
Almirall generates revenue by developing, licensing, manufacturing, and selling prescription medicines, with a strategic focus on medical dermatology across Europe and selected international markets.
- Prescription product sales – The core revenue stream comes from medicines prescribed by physicians and dispensed through pharmacies, hospitals, and healthcare providers.
- Medical dermatology focus – The portfolio targets chronic and high-need skin conditions, including acne, psoriasis, atopic dermatitis, and actinic keratosis.
- European commercial platform – Almirall uses its established sales, regulatory, and market-access infrastructure to commercialize products across European markets.
- Licensing and partnerships – The company supplements internal research with in-licensed assets and strategic partnerships, creating additional product and geographic monetization opportunities.
Revenue Model:
- Sales of prescription dermatology medicines through healthcare and pharmacy channels
- Commercialization of proprietary and in-licensed pharmaceutical products
- Partnering, licensing, and milestone-related income from selected products and markets
Customer / User Types
45%
Pharmacies and pharmaceutical distributors
Primary commercial channels that purchase, distribute, and dispense Almirall's prescription medicines.
20%
Hospitals and healthcare institutions
Institutional customers that procure dermatology and other specialty medicines for patients and clinical use.
25%
Physicians and dermatologists
Key prescribing stakeholders who determine treatment selection and drive demand for the company's products.
10%
Patients
End users of the medicines, generally accessing products through prescriptions and reimbursement systems rather than direct purchases.
💎
Competitive Advantage
Specialized expertise and brand recognition in medical dermatology
Focused portfolio addressing chronic and underserved skin conditions
Established European sales, regulatory, and market-access infrastructure
Recurring demand supported by long-term treatment needs
Ability to combine internal research with external licensing and partnerships
Experienced physician and dermatologist relationships that support adoption